Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00779350 · ClinicalTrials.gov registry record · NA

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fasting Conditions

A NA study, sponsored by Ranbaxy Laboratories Limited.

Completed
Registry status
NA
Development phase
36
Enrollment target

NCT00779350: Completed NA study, sponsored by Ranbaxy Laboratories Limited.

NCT00779350 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00779350, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target

Study Summary

The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under fasted conditions in healthy male and female adult subjects.

Interventions

  • DRUG sertraline 100 mg tablets

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2005-08
Est. Completion 2005-10
Phase NA

Sponsor

Ranbaxy Laboratories Limited

44 total trials

What the Registry Record Tells You About NCT00779350

The ClinicalTrials.gov registry entry for NCT00779350 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which sertraline 100 mg tablets is the first listed.

NCT00779350 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00779350 about?

NCT00779350 is a clinical study titled "Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fasting Conditions". The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under fasted conditions in healthy male and female adult subjects.

What is the current status of trial NCT00779350?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2005-08. Estimated completion is 2005-10.

What interventions are being tested in trial NCT00779350?

The interventions under investigation include: sertraline 100 mg tablets (DRUG).

Who is sponsoring clinical trial NCT00779350?

This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.